Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant Help Center Crisis
Powered By
Real members of MyLungCancerTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

Has anyone tried or heard about this treatment for SCLC? Tarlatamab-dlle (Imdelltra) FDA approved this targeted immunotherapy in May 2024.

A MyLungCancerTeam Member asked a question 💭
Detroit, MI

Tarlatamab-dlle (Imdelltra)
The FDA approved this targeted immunotherapy in May 2024 for patients with extensive stage SCLC that has not responded to chemotherapy. Tarlatamab is a bispecific T-cell engager (BiTE) that attaches to a T-cell and a cancer cell, allowing the T-cell to destroy the cancer cell. However, tarlatamab can cause serious side effects, including cytokine release syndrome (CRS) and neurologic toxicity. Patients may need to be hospitalized to manage these side effects.

October 27, 2024
 · 
Reactions
A MyLungCancerTeam Member

Does anyone know where one could get this treatment in Michigan?

October 27, 2024
MyLungCancerTeam

Yes, Tarlatamab-dlle (Imdelltra) is an FDA-approved treatment for extensive stage small cell lung cancer (SCLC) that has progressed after platinum-based chemotherapy. Here are some key points about this treatment:

- Approval Date: May 2024
- Mechanism: It is a bispecific T-cell engager (BiTE) that targets the DLL3 protein Show Full Answer

Yes, Tarlatamab-dlle (Imdelltra) is an FDA-approved treatment for extensive stage small cell lung cancer (SCLC) that has progressed after platinum-based chemotherapy. Here are some key points about this treatment:

- Approval Date: May 2024.
- Mechanism: It is a bispecific T-cell engager (BiTE) that targets the DLL3 protein on cancer cells and activates T-cells to destroy these cells.
- Administration: Given as an intravenous (IV) infusion.
- Side Effects: Common side effects include fatigue, fever, altered taste, decreased appetite, musculoskeletal pain, constipation, anemia, and nausea. Serious side effects can include cytokine release syndrome (CRS) and neurologic toxicity, which may require hospitalization.

Patients are closely monitored during the initial doses to manage potential side effects.

October 27, 2024
A MyLungCancerTeam Member

Hi Randy, did you end up going on this new treatment from Amgen tarlatamab?
I’m trying to locate others who have used this newest immunotherapy. I’m not sure if I do a separate question but I’ll try here since yours has posted.
I would like to know if you or anyone has tried this and has had bad side effects from it?
My sister had small problems for the 1st 2 doses, then the 3rd dose more problems, besides fatigue, weakness and difficulties that go with sadly stage 4 cancer =( Fell down couldn’t get herself up, shakey hands now. Just sadly it has really made this carat difficult situation much more so. Fell down many times unable to get up.
She then ended up in hospital for 4 days as her whole body seems to be affected. She has now been transferred to a skilled nursing rehab to work on getting stronger and her mobility back.
She had done of the smaller side affects and I was worried for her to continue but Dr.s said it was fine to go with another round, she was 1 of 3 that just started this in a Las Vegas oncology office. Please let me know if you or anyone you know have tried this new RX. I’m praying for her strength and mobility to return.
Thanks for your time and anyone’s help
Sincerely, Karen V

March 19

Related Questions

View All

Thoughts on tralatamab?

A MyLungCancerTeam Member asked a question 💭
Ohio, OH
June 29

What is the latest sclc treatment just approved last fall

A MyLungCancerTeam Member asked a question 💭
61350
March 31, 2025

New Lung Cancer Treatments: 9 Advancements in Research
Lung Cancer Treatment Options
Immunotherapy for Lung Cancer: 4 Types and How They Work